首页 正文

Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis

{{output}}
Background: SGLT2 inhibitors (SGLTi) confer significant cardiometabolic benefits in diabetes, but are associated with increased risk of diabetic ketoacidosis (DKA). We hypothesized that supporting anaplerosis with glycerol could ... ...